Company / Accounts Receivable
Moderna Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$184.0M
FY2025
5-year range
$184.0M / $3.2B
FY2021-FY2025
Trend
-48.6%
vs FY2024
Sector context
#35 of 113
Health Care
What the data says
At $184M, Moderna's accounts receivable ranks #35 of 113 in the Health Care sector. Accounts Receivable has declined for 4 consecutive years, from $3.2B in FY2021 to $184M in FY2025.
Based on SEC 10-K filings.
$184M in FY2025 with a 5-year CAGR of -33.3%.
Declined from $892M to $184M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -49.0%
- 5-Year CAGR
- -33.3%
- 10-Year CAGR
- -
Sector benchmark
#35 of 113 in Health CareTop 31% of 113This company $184.0M Sector average $1.1B
▼
-83.8% below sector average
Key checks
Key Insights
- Moderna's accounts receivable has declined for 4 consecutive years.
- 5-year CAGR of -33.3%, indicating a declining trend.
- In FY2025, accounts receivable decreased 48.6% year-over-year.
- Ranks #35 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $184.0M | -48.6% |
| FY2024 | $358.0M | -59.9% |
| FY2023 | $892.0M | -35.6% |
| FY2022 | $1.4B | -56.4% |
| FY2021 | $3.2B | +128.3% |
| FY2020 | $1.4B | +25808.0% |
| FY2019 | $5.4M | -54.1% |
| FY2018 | $11.7M | -1.6% |
| FY2017 | $11.9M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026